Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Relay Therapeutics, Inc. (RLAY)
A forensic read on Relay Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
3.0
Altman Z-score
Clean
Earnings quality
4
Forensic signals
-43.9%
ROE
$3.6B
Market cap
Relay Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is 3.0, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by receivables vs revenue.
What the filings flag
81d DSOReceivables vs revenue.Days sales outstanding moved from 49 to 81 days FY2021→FY2022 (receivables -24% vs revenue -54%). Receivables are outrunning sales — a flag for aggressive revenue recognition or slipping collections.
-47%Return on invested capital.Return on invested capital is -47% and slipping from -27% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+81.7%/yrShare-count dilution.Diluted share count changed +163% over the last 2 years to FY2022 (+81.7%/yr). The count is GROWING — existing holders are being diluted. That's ~81.7% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2020 has been diluted ~163%.
407% of revStock-based comp load.Stock-based compensation ran 407% of revenue in FY2025. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-1800.6%
Free Cash Flow$-235.9M
Latest Revenue$15.4M
Return on Equity-48.8%
Revenue Growth YoY+53.4%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Relay Therapeutics, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about RLAY's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown